Bio-Clinaarc Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -54.13%
- Profit Growth -21.01%
- Ebitda 35.44%
- Net Worth 4.87%
- Total Assets 102.65%
About Bio-Clinaarc
Bio-Clinaarc Private Limited (BPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 October 2015 (Nine years and four months 12 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Corporate was formerly known as Bio-Clingene Research Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anilkumar Meshram, Suman Meshram, and Rajeshkumar Babulal serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U72900MH2015PTC268917
-
Company No.
268917
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Oct 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Bio-Clinaarc?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anilkumar Meshram
|
Director | 05-Oct-2015 | Current |
|
Suman Meshram
|
Director | 05-Oct-2015 | Current |
|
Rajeshkumar Babulal
|
Director | 01-Aug-2024 | Current |
Financial Performance of Bio-Clinaarc.
Bio-Clinaarc Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 54.13% decrease. The company also saw a substantial fall in profitability, with a 21.01% decrease in profit. The company's net worth moved up by a moderate rise of 4.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio-Clinaarc?
In 2021, Bio-Clinaarc had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Iicrm Private LimitedSuman Meshram is a mutual person
-
Skyleap Life Science Technologies Private Limited
Suman Meshram is a mutual person
-
Lybra Clinical Research Private Limited
Rajeshkumar Babulal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bio-Clinaarc?
Unlock and access historical data on people associated with Bio-Clinaarc, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio-Clinaarc, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio-Clinaarc's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.